Contribute Try STAT+ Today

Pancreatic cancer often kills people because they are diagnosed too late, after their tumors have spread. Other patients may die following the removal of harmless cysts that appear threatening amid a fog of imaging data and other clinical information.

But a new artificial intelligence system unveiled Wednesday by doctors at Johns Hopkins offers to provide a clearer picture for patients: In testing, it displayed a superhuman ability to differentiate harmful lesions from ones that pose no threat at all.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Curious to note that there is no real discussion of the finding of cysts in the pancreas in patients who may have other cancers, such as renal cancer. Was there any further testing of such ‘cysts’ which may in reality be metastases? As a patient advocate for renal cancer patients, a newly discovered mass in the pancreas of a kidney cancer patient is indeed a a cyst, a new cancer or metastases is not uncommon, both at the time of diagnosis of the renal cancer or during treatment.

  • This type of research is worthy of solid pursuit. Some degree of subjectivity is to be expected with medical AI in-development, but the increased differentiation for decisions between treatments / surgery / agressive approach / wait-and-see is hugely valuable. Highly commendable research !

Comments are closed.